See
Genome Information for Homo sapiens
Assessment of tumor pathological and transcriptional biomarkers in pre- and on-treatment core biopsies predictive of response and outcome after neoadjuvant chemotherapy plus Bevacizumab in patients with HER2-negative breast cancer: Results from a multi-center, single-arm, phase 2 study (the PROMIX trial)
Global gene expression profiling was performed on samples from 3 time points (baseline, after 2 cycles and surgery) from women with breast cancer receivcing neoadjuvant chemotherapy with bevacizumab in a phase 2 trial
Overall design: Multi-center, single-arm, phase 2 study of neoadjuvant anthracycline (epirubicin) plus taxane (docetaxel) with the addition of bevacizumab (avastin) for women with large operable and locally advanced HER2-negative breast cancer.
| Accession | PRJNA344794; GEO: GSE87455 |
| Data Type | Transcriptome or Gene expression |
| Scope | Multiisolate |
| Organism | Homo sapiens[Taxonomy ID: 9606] Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo; Homo sapiens |
| Publications (total 3) Less... | - Kimbung S et al., "Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.", Int J Cancer, 2018 Feb 1;142(3):618-628
More...- Kimbung S et al., "Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.", Int J Cancer, 2018 Feb 1;142(3):618-628
- Matikas A et al., "Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer.", Oncoimmunology, 2018;7(9):e1466017
- Palazon A et al., "An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression.", Cancer Cell, 2017 Nov 13;32(5):669-683.e5
Less... |
| Submission | Registration date: 28-Sep-2016
Breast and Ovarian Cancer Genomics, Div of Omcology & Pathology, Dept of Clinical Sciences, Lund University |
| Relevance | Medical |
Project Data:
| Resource Name | Number
of Links |
|---|
| Publications |
| PubMed | 3 |
| PMC | 3 |
| Other datasets |
| GEO DataSets | 1 |
GEO Data Details| Parameter | Value |
|---|
| Data volume, Spots | 13013825 |
| Data volume, Processed Mbytes | 370 |
| Data volume, Supplementary Mbytes | 74 |